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Clinical PerspectiveWhat Is New?Amino‐terminal pro--brain natriuretic peptide, estimated glomerular filtration rate, and high‐sensitivity C‐reactive protein at admission significantly predicted the development of cardiorenal syndrome type 1 and showed good discriminative ability.The combination of the 3 biomarkers showed better predictive capability than any of the biomarkers individually.Abnormal levels of 2 or more of these markers according to the identified cutoff values were associated with an elevated risk of cardiorenal syndrome type 1.What Are the Clinical Implications?Use of amino‐terminal pro--brain natriuretic peptide, estimated glomerular filtration rate, and high‐sensitivity C‐reactive protein in combination may assist in the prediction of cardiorenal syndrome type 1 and corresponding risk stratification in patients with acute myocardial infarction.

Introduction {#jah33530-sec-0008}
============

Cardiorenal syndrome (CRS) is defined as "a complex pathophysiologic disorder of the heart and kidneys where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ."[1](#jah33530-bib-0001){ref-type="ref"}, [2](#jah33530-bib-0002){ref-type="ref"} Five subtypes of CRS have been defined according to the primary organ, an acute versus chronic time frame, and whether cardiac and renal codysfunction occur secondary to systemic disease. CRS type 1 (CRS1) is characterized by acute worsening of heart function leading to acute kidney injury (AKI). The reported incidence of CRS1 ranges from 25% to 33% in patients admitted with acute decompensated heart failure,[3](#jah33530-bib-0003){ref-type="ref"} and the reason for this variation may be the differences in the definitions of kidney dysfunction and the heterogeneity of populations. The pathophysiology of CRS1 is multifaceted and involves both hemodynamic and nonhemodynamic mechanisms that remain largely unknown.[4](#jah33530-bib-0004){ref-type="ref"} However, it has been shown that passive central venous congestion and inflammatory activation play vital roles in the mechanisms leading to CRS1 in patients with acute heart failure.[5](#jah33530-bib-0005){ref-type="ref"}, [6](#jah33530-bib-0006){ref-type="ref"}, [7](#jah33530-bib-0007){ref-type="ref"}

AKI is 1 of the most frequent in‐hospital complications in patients with acute myocardial infarction (AMI) and is associated with adverse short‐term and long‐term outcomes.[8](#jah33530-bib-0008){ref-type="ref"}, [9](#jah33530-bib-0009){ref-type="ref"} At the same time, AMI is a common antecedent event that predisposes patients to acute heart failure. Patients who experience both acute heart failure and AKI have worse outcomes than those who experience only 1 of these conditions.[10](#jah33530-bib-0010){ref-type="ref"} Therefore, there is an urgent need to understand the risk factors for CRS1 and to establish an ideal biomarker for its prediction in AMI patients. Over the past decade researchers have evaluated many traditional and novel biomarkers, such as serum creatinine, cystatin C, the urea albumin creatinine ratio, neutrophil gelatinase‐associated lipocalin, and others. However, whether these biomarkers possess adequate prognostic accuracy for early detection of CRS1 remains to be determined. Moreover, a multimarker panel may provide a more effective model for CSR1 risk prediction.

Toward the development of such a biomarker panel, we selected amino‐terminal pro--brain natriuretic peptide (NT‐proBNP), the estimated glomerular filtration rate (eGFR), and high‐sensitivity C‐reactive protein (hs‐CRP) as promising markers of heart failure, renal injury, and inflammation, respectively, and investigated the predictive value of these biomarkers individually and in combination for CRS1 in AMI patients.

Methods {#jah33530-sec-0009}
=======

The data, analytic methods, and study materials for this study will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The materials will be made available by the corresponding author on reasonable request.

Study Population {#jah33530-sec-0010}
----------------

The study population for this retrospective, single‐center observational study was identified from the AMI patient database of the Cardiovascular Center of Beijing Friendship Hospital, which includes patients treated from 2012 onward. From December 2012 to February 2017, 2712 patients were included in the database according to the following criteria: age of more than 18 years, confirmed diagnosis of AMI presenting with ST‐segment elevation myocardial infarction or non--ST‐elevation myocardial infarction and treated within 48 hours after the onset of symptoms. All medical data and study end points were collected by trained study coordinators. AMI was defined according to published guidelines.[11](#jah33530-bib-0011){ref-type="ref"}, [12](#jah33530-bib-0012){ref-type="ref"} The study protocol was performed in accordance with the principles of the Declaration of Helsinki and was approved by the local institutional ethics committee with a waiver for informed consent (No. 2017‐P2‐123‐01), and permission was granted to use data for analysis. For the present analysis, exclusion criteria included (1) chronic renal failure and/or need for regular hemodialysis (n=22) or peritoneal dialysis (n=6); (2) serum creatinine ≥442 μmol/L at first admission (n=9); (3) prior treatment with renal transplantation (n=1); (4) presence of autoimmune disease and sepsis that might result in worsening renal function (n=6); and (5) absence of either the initial or peak creatinine values and admission data (n=574). According to these criteria, this study population consisted of the remaining 2094 patients (Figure [1](#jah33530-fig-0001){ref-type="fig"}).

![Selection of patient population. AMI indicates acute myocardial infarction; CBD, Cardiovascular Center of Beijing Friendship Hospital Database; CRS1, cardiorenal syndrome type 1.](JAH3-7-e009162-g001){#jah33530-fig-0001}

Data Collection and Biomarker Assays {#jah33530-sec-0011}
------------------------------------

On the basis of renal function and cardiac function, patients were assigned to either the CRS1 or no‐CRS1 group. The collected clinical data included (1) basic information including age, sex, duration of hospitalization (days), classification of AMI, blood pressure, heart rate at admission, and body mass index at admission; (2) a medical history including coronary artery disease, percutaneous revascularization, coronary artery bypass grafting, hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, peripheral arterial disease, and stroke; (3) treatment and prognosis involving an intra‐aortic balloon pump, percutaneous revascularization, drug intervention (angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker \[ACEI/ARB\], diuretic, antiplatelet agent, β‐blocker, statins), and clinical outcomes; (4) laboratory data and auxiliary examinations at admission, such as levels of NT‐proBNP, creatinine, hs‐CRP, hemoglobin, hematocrit, albumin, glucose, and glycated hemoglobin. NT‐proBNP levels were assays based on a chemiluminescence enzyme immune assay and MAGTRATION methodology, and measurements were taken by a PATHFAST NT‐proBNP analyzer (Mitsubishi Kagaku Iatron, Tokyo, Japan). Serum creatinine concentrations were measured using a picric acid method and Beckman Coulter analyzers (Beckman Coulter Inc, Brea, CA). The hs‐CRP was measured by an ultrasensitive method based on particle‐enhanced immunoturbidimetry (DiaSys Diagnostic System, Holzheim, Germany). Troponin I was measured every 3 to 6 hours, and the peak value for each case was recorded. All the patients underwent echocardiography examination on admission, and the left ventricular ejection fraction was acquired via the modified Simpson method.

Heart Function and Kidney Function: CRS Definition {#jah33530-sec-0012}
--------------------------------------------------

Heart function was evaluated using the Killip‐Kimball classification during the episode, and heart failure was identified if the patient was considered class II or higher. Patients\' eGFRs were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.[13](#jah33530-bib-0013){ref-type="ref"} AKI was determined using the Acute Kidney Injury Network criteria[14](#jah33530-bib-0014){ref-type="ref"} and defined as an increase in serum creatinine of ≥0.3 mg/dL or 1.5‐fold higher than normal. The baseline serum creatinine was obtained on admission. For some patients, the serum creatinine concentration at discharge was lower than that at admission, and the serum creatinine concentration was considered to be the basal concentration. CRS1 was defined by the sum of these 2 components.[15](#jah33530-bib-0015){ref-type="ref"}, [16](#jah33530-bib-0016){ref-type="ref"} Acute heart failure was followed by AKI; that is, with a Killip--Kimball score ≥II and AKI. The primary end point of this study was the development of CRS1 during hospitalization.

Statistical Analysis {#jah33530-sec-0013}
--------------------

Continuous variables appeared to have non‐Gaussian distributions, and therefore, the data are presented as median values with interquartile ranges. Comparisons between the study groups were performed by nonparametric rank test (Mann‐Whitney U‐test). Categorical variables are presented as numbers and percentages, and the chi‐squared test was used to compare variables between the study groups. Because the distribution of NT‐proBNP was highly skewed, log transformation of the data was carried out.

Logistic regression analysis was used to obtain odds ratios (ORs) and 95% confidence intervals (CIs) for the development of CRS1. To determine the factors that could independently predict CRS1, variables that were significant in the univariate logistic regression analysis were incorporated into the multivariate logistic regression analysis. Multivariable analysis was performed to evaluate the effects of the number of abnormal biomarker levels on the risk of developing CRS1.

The receiver operating characteristic (ROC) curve analysis was used to evaluate the discriminatory capability of the biomarkers for CRS1. To control for confounding factors, covariates were included in the ROC analysis, and propensity score matching analysis was performed. The cutoff value was defined for the maximum Youden index. Statistical analyses were performed with using SPSS version 19.0 (SPSS, Chicago, IL) and Med‐calc software version 15.8 (MedCalc Software bvba, Mariakerke, Belgium). A 2‐sided *P* value of less than 0.05 was considered to indicate a statistically significant difference.

### Propensity Score Matching Analysis {#jah33530-sec-0014}

Propensity score matching is used to reduce selection bias in observational studies. The matching process was conducted with a minimum‐distance scoring method and a 1‐to‐1 match between the CRS1 group and the no‐CRS1 group. In this study, propensity scores were calculated through a binary logistic regression model, including covariates of age, sex, hemoglobin, hematocrit, albumin, glucose, previous coronary artery disease, previous hypertension, previous diabetes mellitus, previous chronic kidney disease, angiography, ACEI and/or ARB use after admission, and diuretic use after admission. Ultimately, 120 CRS1 patients were individually matched to 120 no‐CRS1 controls using nearest available score matching with SPSS version 22.0. The ROC curve analysis from the data set after matching was used to further evaluate the discriminatory capability of the biomarkers for CRS1.

Results {#jah33530-sec-0015}
=======

Patient Characteristics and the Prevalence of CRS1 {#jah33530-sec-0016}
--------------------------------------------------

A total of 2094 patients presenting with AMI from December 2012 to February 2017 were included in this study. Among the affected inpatients, 656 (31.33%) developed acute heart failure, and 177 (8.45%) developed CRS1. A total of 63 (3%) patients died during hospitalization, and all‐cause mortality was higher among those with CRS1 than among those without (17.5% versus 1.7%; *P*\<0.001).

The demographic, clinical, and laboratory characteristics of the patients with and without CRS1 are provided in Table [1](#jah33530-tbl-0001){ref-type="table"}. There were no significant differences between the groups in the incidence of ST‐elevation myocardial infarction, systolic blood pressure, diastolic blood pressure, prior percutaneous revascularization, dyslipidemia, or peak serum levels of troponin I and glycated hemoglobin. Compared with the patients without CRS1, patients who developed CRS1 were older, more often female, had a longer hospital stay, and more frequently presented with a medical history of coronary artery disease, coronary artery bypass grafting, hypertension, diabetes mellitus, chronic kidney disease, peripheral arterial disease, or stroke. The CRS1 group also had higher mean levels of NT‐proBNP (5324.0 versus 626.5 pg/mL; *P*\<0.001), creatinine (113.0 versus 77.0 μmol/L; *P*\<0.001), hs‐CRP (16.5 versus 5.9 mg/L; *P*\<0.001), and glucose (8.5 versus 7.8 mmol/L; *P*=0.043), as well as lower levels of hemoglobin (124 versus 135 g/L; *P*\<0.001), hematocrit (37.4% versus 40.5%; *P*\<0.001), and albumin (36.4 versus 39.0 g/dL; *P*\<0.001) and a lower eGFR (50.5 versus 85.6 mL/\[min·1.73 m^2^\]; *P*\<0.001). It should be noted that the treatment after admission was significantly different. A higher percentage of patients with CRS1 were treated with an intra‐aortic balloon pump and diuretics (*P*\<0.001), whereas treatments involving an ACEI and/or ARB, antiplatelet agent, β‐blocker, statins, angiography, and percutaneous revascularization were used more often in patients without CRS1 (all *P*\<0.001).

###### 

Distribution of Variables in Patients With AMI According to the Development of CRS1

  Characteristic                                    Total (N=2094)          NO CRS1 (n=1917)        CRS1 (n=177)                 *P* Value
  ------------------------------------------------- ----------------------- ----------------------- ---------------------------- -----------
  Age, y (median, interquartile range)              65 (57, 77)             64 (56, 76)             77 (67, 82)                  \<0.001
  Female (n, %)                                     612 (29.2)              541 (28.2)              71 (40.1)                    0.001
  Hospital stay, d (median, interquartile range)    8 (6, 10)               7 (6, 9)                10 (7, 14)                   \<0.001
  STEMI (n, %)                                      1003 (47.9)             916 (47.8)              87 (49.2)                    0.727
  Measurements (median, interquartile range)                                                                                     
  Systolic blood pressure at admission, mm Hg       130 (114, 143)          130 (115, 143)          125 (111, 148)               0.509
  Diastolic blood pressure at admission, mm Hg      73 (65, 81)             73 (65, 81)             71 (64, 80)                  0.142
  Heart rate at admission, bpm                      74 (65, 82)             74 (65, 84)             83 (69, 97)                  \<0.001
  Body mass index, kg/m^2^                          25.4 (23.0, 27.7)       25.4 (23.1, 27.7)       24.3 (21.0, 27.6)            0.009
  Left ventricular ejection fraction, %             62 (53, 67)             62 (55, 67)             50 (35, 64)                  \<0.001
  Laboratory values (median, interquartile range)                                                                                
  Hemoglobin at admission, g/L                      134 (121, 148)          135 (122, 148)          124 (104.8136.0)             \<0.001
  Hematocrit at admission, %                        40.2 (36.3, 44.0)       40.5 (36.6, 44.3)       37.4 (32.2, 41.1)            \<0.001
  Albumin at admission, g/dL                        38.9 (35.8, 41.7)       39.0 (36.0, 41.8)       36.4 (33.4, 39.7)            \<0.001
  NT‐proBNP at admission, pg/mL                     738.0 (207.5, 2817.5)   626.5 (193.0, 2236.8)   5324.0 (2 357.5, 17 730.5)   \<0.001
  Creatinine at admission, μmol/L                   78.0 (68.0, 96.3)       77.0 (67.5, 92.3)       113.0 (89.0147.5)            \<0.001
  eGFR at admission, mL/(min/1.73 m^2^)             83.6 (64.3100.3)        85.6 (67.6101.5)        50.5 (32.9, 68.1)            \<0.001
  Peak troponin I, ng/mL                            4.9 (1.1, 16.1)         3.9 (0.8, 12.4)         5.5 (1.3, 18.9)              0.081
  Glucose at admission, mmol/L                      7.9 (6.4, 10.8)         7.8 (6.4, 10.7)         8.5 (6.6, 11.8)              0.043
  hs‐CRP at admission, mg/L                         6.6 (2.3, 17.3)         5.9 (2.2, 15.7)         16.5 (8.1, 30.1)             \<0.001
  Glycated hemoglobin at admission, %               6.0 (5.5, 7.1)          6.0 (5.5, 7.0)          6.2 (5.7, 7.4)               0.055
  Medical history (n, %)                                                                                                         
  Coronary artery disease                           828 (39.5)              737 (38.4)              91 (51.4)                    0.001
  Percutaneous revascularization                    326 (15.6)              290 (15.1)              36 (20.3)                    0.067
  Coronary artery bypass grafting                   45 (2.1)                34 (1.8)                11 (6.2)                     \<0.001
  Hypertension                                      1383 (66.0)             1244 (64.9)             139 (78.5)                   \<0.001
  Diabetes mellitus                                 710 (33.9)              633 (33.0)              77 (43.5)                    0.005
  Dyslipidemia                                      934 (44.6)              849 (44.3)              85 (48.0)                    0.339
  Chronic kidney disease                            118 (5.6)               81 (4.2)                37 (20.9)                    \<0.001
  Peripheral arterial disease                       124 (5.9)               99 (5.2)                25 (14.1)                    \<0.001
  Stroke                                            356 (17.0)              316 (16.5)              40 (22.6)                    0.038
  Treatment after admission (n, %)                                                                                               
  IABP                                              41 (2.0)                30 (1.6)                11 (6.2)                     \<0.001
  Angiography                                       1669 (79.7)             1587 (82.8)             82 (46.3)                    \<0.001
  Percutaneous revascularization                    1482 (70.8)             1417 (73.9)             65 (36.7)                    \<0.001
  ACEI and/or ARB                                   1426 (68.1)             1339 (69.8)             87 (49.2)                    \<0.001
  Diuretics                                         309 (14.8)              239 (12.5)              70 (39.5)                    \<0.001
  Antiplatelet agent                                1942 (92.7)             1810 (94.4)             132 (74.6)                   \<0.001
  β‐blocker                                         1512 (72.2)             1410 (73.6)             102 (57.6)                   \<0.001
  Statins                                           1802 (86.1)             1686 (87.9)             116 (65.5)                   \<0.001
  Clinical end points (n, %)                                                                                                     
  All‐cause mortality                               63 (3.0)                32 (1.7)                31 (17.5)                    \<0.001
  Cardiac mortality                                 56 (2.7)                27 (1.4)                29 (16.4)                    \<0.001

ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; bpm, beats/min; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; IABP, intra‐aortic balloon pump; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide; STEMI, ST‐segment--elevation myocardial infarction.

Predictors of CRS1 {#jah33530-sec-0017}
------------------

Table [2](#jah33530-tbl-0002){ref-type="table"} shows the results of the univariate and multivariate logistic regression analyses. On univariate analysis, increased log(NT‐proBNP) and hs‐CRP levels and decreased eGFR at admission were significantly associated with CRS1, as were advanced age, female sex, history of coronary artery disease, hypertension, diabetes mellitus, chronic kidney disease, decreased hemoglobin, hematocrit, and albumin, angiography use, ACEI and/or ARB use, increased glucose, and diuretic use. After multivariable adjustment, increased log(NT‐proBNP) (OR 2.136; 95% CI 1.422‐3.209; *P*\<0.001), glucose (OR 1.003; 95% CI 1.000‐1.006; *P*=0.03), and hs‐CRP (OR 1.031; 95% CI 1.014‐1.048; *P*\<0.001) as well as diuretic use (OR 1.811; 95% CI 1.130‐2.902; *P*=0.014), decreased eGFR (OR 0.967; 95% CI 0.956‐0.979; *P*\<0.001), and ACEI and/or ARB use (OR 0.509; 95% CI 0.328‐0.789; *P*=0.003) were determined to be independent predictors of CRS1 in AMI patients.

###### 

Univariate and Multivariate Logistic Regression Analysis of CRS1 Occurrence in Patients With AMI

                                          Univariate            Multivariate                                                                
  --------------------------------------- --------------------- -------------- ------------------------------------------------------------ ---------
  Age, y                                  1.073 (1.057‐1.089)   \<0.001        1.021 (0.999‐1.045)                                          0.065
  Female, %                               1.704 (1.241‐2.338)   0.001          0.801 (0.503‐1.276)                                          0.350
  Hemoglobin at admission, g/dL           0.969 (0.962‐0.977)   \<0.001        1.016 (0.974‐1.060)                                          0.458
  Hematocrit at admission, %              0.897 (0.874‐0.921)   \<0.001        0.978 (0.848‐1.128)                                          0.763
  Albumin at admission, g/dL              0.892 (0.862‐0.923)   \<0.001        1.041 (0.986‐1.099)                                          0.146
  log(NT‐proBNP) at admission             6.005 (4.524‐7.971)   \<0.001        2.136 (1.422‐3.209)[a](#jah33530-note-0003){ref-type="fn"}   \<0.001
  eGFR at admission, mL/(min·1.73 m^2^)   0.95 (0.943‐0.956)    \<0.001        0.967 (0.956‐0.979)[b](#jah33530-note-0004){ref-type="fn"}   \<0.001
  Glucose at admission, mmol/L            1.003 (1.001‐1.005)   0.002          1.003 (1.000‐1.006)                                          0.03
  hs‐CRP at admission, mg/L               1.046 (1.035‐1.059)   \<0.001        1.031 (1.014‐1.048)[c](#jah33530-note-0005){ref-type="fn"}   \<0.001
  Previous coronary artery disease        1.694 (1.244‐2.307)   0.001          1.067 (0.691‐1.646)                                          0.770
  Previous hypertension                   1.979 (1.366‐2.867)   \<0.001        1.378 (0.813‐2.334)                                          0.234
  Previous diabetes mellitus              1.562 (1.143‐2.137)   0.005          0.666 (0.397‐1.116)                                          0.123
  Previous chronic kidney disease         5.99 (3.916‐9.165)    \<0.001        1.771 (0.924‐3.396)                                          0.085
  Angiography after admission             0.179 (0.131‐0.247)   \<0.001        0.744 (0.460‐1.202)                                          0.227
  ACEI and/or ARB after admission         0.417 (0.306‐0.569)   \<0.001        0.509 (0.328‐0.789)                                          0.003
  Diuretics after admission               4.593 (3.301‐6.391)   \<0.001        1.811 (1.130‐2.902)                                          0.014

ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide; OR, odds ratio.

The odds ratio and 95%CI for 1 standard deviation change in the logNT‐proBNP were 1.792 (1.311--2.450).

The odds ratio and 95%CI for 1 standard deviation change in the eGFR was 0.424 (0.310--0.576).

The odds ratio and 95%CI for 1 standard deviation change in the hs‐CRP was 1.429 (1.180--1.747).

ROC Curve Analysis of the Value of NT‐proBNP, eGFR, and hs‐CRP, as Biomarkers {#jah33530-sec-0018}
-----------------------------------------------------------------------------

The results of the ROC analysis detailed in Table [3](#jah33530-tbl-0003){ref-type="table"} revealed that all 3 biomarkers significantly predicted the development of CRS1 (area under the ROC curve \[AUC\]: NT‐proBNP 0.813, eGFR 0.828, and hs‐CRP 0.693; all *P*\<0.01). According to the maximum Youden indexes, the cutoff values for eGFR, NT‐proBNP, and hs‐CRP were 71.29 mL/\[min·1.73 m^2^\], 2573 pg/mL, and 8.03 mg/L, respectively. Notably, the specificity of hs‐CRP (57.04%) was less than those of eGFR (71.31%) and NT‐proBNP (77.82%). The AUC for the combination of eGFR, NT‐proBNP, and hs‐CRP was 0.856 (*P*\<0.01), indicating very good discriminative ability for the prediction of CRS1. Table [4](#jah33530-tbl-0004){ref-type="table"} shows the results of the covariate adjusted model analysis. After including the covariates, the biomarkers individually and together still significantly predicted CRS1 with AUC values of 0.858 for log(NT‐proBNP), 0.866 for eGFR, 0.849 for hs‐CRP, and 0.882 for the combination of these 3 markers (all *P*\<0.001). The differences in the AUC values between the individual biomarkers and their combinations (Figure [2](#jah33530-fig-0002){ref-type="fig"}) were statistically significant (*P*\<0.05), which indicated that the predictive capability of the 3‐biomarker panel is better than each individual marker.

###### 

Prematching Receiver Operating Characteristic Curve Analysis of NT‐proBNP, eGFR, and hs‐CRP for the Prediction of CRS1

                                          Cutoff Value   Abnormality (n, %)[a](#jah33530-note-0008){ref-type="fn"}   AUC          *P* Value   95% CI    Sensitivity      Specificity   Youden Index   
  --------------------------------------- -------------- ----------------------------------------------------------- ------------ ----------- --------- ---------------- ------------- -------------- -------
  eGFR at admission, mL/(min·1.73 m^2^)   71.29          550 (28.7)                                                  142 (80.2)   0.828       \<0.001   0.811 to 0.844   0.8079        0.7131         0.521
  NT‐proBNP at admission, pg/mL           2573           385 (22.2)                                                  120 (74.5)   0.813       \<0.001   0.777 to 0.849   0.7453        0.7782         0.524
  hs‐CRP at admission, mg/L               8.03           806 (43.0)                                                  125 (76.2)   0.693       \<0.001   0.653 to 0.733   0.7622        0.5704         0.333
  NT‐proBNP +eGFR+ hs‐CRP                 ···            ···                                                         ···          0.856       \<0.001   0.825 to 0.886   ···           ···            ···

AUC indicates area under the receiver operating characteristic curve; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.

Abnormal biomarkers levels were defined as eGFR≤71.29 mL/(min·1.73 m^2^), NT‐proBNP≥2573 pg/mL, and hs‐CRP≥8.03 mg/L individually.

###### 

Prematching Receiver Operating Characteristic Curve Analysis of NT‐proBNP, eGFR, and hs‐CRP Adjusted by Covariates for the Prediction of CRS1

                                          AUC     *P* Value   95% CI
  --------------------------------------- ------- ----------- ----------------
  Covariates                              0.837   \<0.001     0.804 to 0.870
  eGFR+ covariates                        0.866   \<0.001     0.850 to 0.881
  Log(NT‐proBNP)+covariates               0.858   \<0.001     0.824 to 0.892
  hs‐CRP+ covariates                      0.849   \<0.001     0.832 to 0.865
  Log(NT‐proBNP)+eGFR+hs‐CRP+covariates   0.882   \<0.001     0.850 to 0.913

The covariates included age, sex, hemoglobin, hematocrit, albumin, glucose, previous coronary artery disease, previous hypertension, previous diabetes mellitus, previous chronic kidney disease, angiography, ACEI and/or ARB use after admission, and diuretic use after admission. The differences in the AUC values adjusted by covariates between the individual biomarkers and their combinations were statistically significant, with *P* values of 0.0330 (eGFR+covariates vs Log\[NT‐proBNP\]+eGFR+hs‐CRP+covariates), 0.0070 (Log\[NT‐proBNP\]+covariates vs Log\[NT‐proBNP\]+eGFR+hs‐CRP+covariates), 0.0062 (hs‐CRP+covariates vs Log\[NT‐proBNP\]+eGFR+hs‐CRP+covariates), and 0.0008 (covariates vs Log\[NT‐proBNP\]+eGFR+hs‐CRP+covariates). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; AUC, area under the receiver operating characteristic curve; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.

![Prematching receiver operating characteristic curve analysis including covariates for the prediction of CRS1 by eGFR,NT‐proBNP, and hs‐CRP. CRS1 indicates cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.](JAH3-7-e009162-g002){#jah33530-fig-0002}

After propensity score matching, the baseline age and sex along with hemoglobin, hematocrit, albumin, glucose, history of coronary artery disease, hypertension, diabetes mellitus, chronic kidney disease, angiography use, ACEI and/or ARB use, and diuretic use were not statistically different between the CRS1 and no‐CRS1 groups (Table [5](#jah33530-tbl-0005){ref-type="table"}). The results of ROC analysis (Table [6](#jah33530-tbl-0006){ref-type="table"}, Figure [3](#jah33530-fig-0003){ref-type="fig"}) still showed that the discriminatory capability of the 3‐biomarker panel was good (AUC 0.863, 95% CI 0.816‐0.910) and stronger than that of the individual biomarkers, with AUC values of 0.719 for NT‐proBNP, 0.843 for eGFR, and 0.656 for hs‐CRP (all *P*\<0.001).

###### 

Pre‐ and Postmatching Distribution of Covariates in Patients With AMI According to the Development of CRS1

  Covariate                                    Prematching         Postmatching                                                              
  -------------------------------------------- ------------------- ------------------- ----------- -------------------- -------------------- -------
  Age, y (median, IQR)                         64 (56, 76)         77 (67, 82)         \<0.001     74 (61, 81)          76.5 (67, 82)        0.091
  Min/max                                      25/99               42/98               ···         29/99                50/91                ···
  ≤60 (n, %)                                   741 (38.7)          22 (12.4)           \<0.001     27 (22.5)            16 (13.3)            0.122
  61 to 70 (n, %)                              513 (26.8)          34 (19.2)           24 (20.0)   22 (18.3)                                 
  71 to 80 (n, %)                              405 (21.1)          59 (33.3)           32 (26.7)   47 (39.2)                                 
  ≥81 (n, %)                                   258 (13.5)          62 (35.0)           37 (30.8)   35 (29.2)                                 
  Female (n, %)                                541 (28.2)          71 (40.1)           0.001       36 (30)              48 (40)              0.104
  Hemoglobin at admission, g/L (median, IQR)   135 (122, 148)      124 (104.8136.0)    \<0.001     129 (117.3142.8)     126 (110, 137.8)     0.171
  Hematocrit at admission, % (median, IQR)     40.5 (36.6, 44.3)   37.4 (32.2, 41.1)   \<0.001     38.55 (35.4, 43.0)   38.35 (33.5, 42.0)   0.195
  Albumin at admission, g/dL (median, IQR)     39.0 (36.0, 41.8)   36.4 (33.4, 39.7)   \<0.001     37.9 (33.9, 40.7)    37.45 (34.5, 39.9)   0.677
  Glucose at admission, mmol/L (median, IQR)   7.8 (6.4, 10.7)     8.5 (6.6, 11.8)     0.043       8.8 (6.7, 13.9)      8.6 (6.5, 12.1)      0.366
  Previous coronary artery disease (n, %)      737 (38.4)          91 (51.4)           0.001       55 (45.8)            60 (50)              0.518
  Previous hypertension (n, %)                 1244 (64.9)         139 (78.5)          \<0.001     89 (74.2)            96 (80)              0.282
  Previous diabetes mellitus (n, %)            633 (33.0)          77 (43.5)           0.005       41 (34.2)            49 (40.8)            0.286
  Previous chronic kidney disease (n, %)       81 (4.2)            37 (20.9)           \<0.001     9 (7.5)              18 (15)              0.066
  Angiography after admission (n, %)           1587 (82.8)         82 (46.3)           \<0.001     61 (50.8)            63 (52.5)            0.796
  ACEI and/or ARB after admission (n, %)       1339 (69.8)         87 (49.2)           \<0.001     57 (47.5)            67 (55.8)            0.196
  Diuretics after admission (n, %)             239 (12.5)          70 (39.5)           \<0.001     55 (45.8)            42 (35)              0.087

ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CRS1, cardiorenal syndrome type 1; IQR, interquartile range.

###### 

Postmatching Receiver Operating Characteristic Curve Analysis of NT‐proBNP, eGFR, and hs‐CRP for the Prediction of CRS1

                                          AUC     *P* Value   95% CI
  --------------------------------------- ------- ----------- ----------------
  eGFR at admission, mL/(min·1.73 m^2^)   0.843   \<0.001     0.792 to 0.894
  NT‐proBNP at admission, pg/mL           0.719   \<0.001     0.654 to 0.784
  hs‐CRP at admission, mg/L               0.656   \<0.001     0.587 to 0.725
  NT‐proBNP+eGFR+hs‐CRP                   0.863   \<0.001     0.816 to 0.910

The differences in the AUC values between the individual biomarkers and their combinations were statistically significant, with *P* values of 0.0372 (eGFR vs NT‐proBNP+eGFR+hs‐CRP), \<0.0001 (NT‐proBNP vs NT‐proBNP+eGFR+hs‐CRP), and \<0.0001 (hs‐CRP vs NT‐proBNP+eGFR+hs‐CRP). AUC indicates area under the receiver operating characteristic curve; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.

![Postmatching receiver operating characteristic curve analysis for the prediction of CRS1 by eGFR,NT‐proBNP, and hs‐CRP. CRS1 indicates cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.](JAH3-7-e009162-g003){#jah33530-fig-0003}

Association Between Number of Abnormal Biomarker Levels and CRS1 {#jah33530-sec-0019}
----------------------------------------------------------------

The data presented in Figure [4](#jah33530-fig-0004){ref-type="fig"} illustrate the association between the number of abnormal biomarker levels and the risk of CRS1. Using the cutoff values derived from the ROC analysis to define biomarker levels as normal or abnormal, the risk of CRS1 increased significantly with an increasing number of abnormal biomarker levels. In a multivariate adjusted logistic regression model, the odds of CRS1 were increased by 35‐fold if patients presented with abnormal levels of 2 or more biomarkers compared with no abnormal levels (Table [7](#jah33530-tbl-0007){ref-type="table"}). This finding implies that abnormal levels of the biomarkers at presentation may facilitate better CRS1 risk stratification.

![Association of the number of abnormal biomarker levels based on the identified cutoff values and the risk of CRS1. The risk of developing CRS1 increased significantly with an increase in the number of biomarkers showing abnormal levels according to the identified cutoff values. CRS1 indicates cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide.](JAH3-7-e009162-g004){#jah33530-fig-0004}

###### 

Multivariable Logistic Regression Analysis of Number of Abnormal Biomarker Levels and the Odds of Developing CRS1

  No. of Abnormal Biomarkers[a](#jah33530-note-0013){ref-type="fn"}   No‐CRS1 (n, %)   CRS1 (n, %)   Adjusted OR (95% CI)[b](#jah33530-note-0014){ref-type="fn"}   *P* Value
  ------------------------------------------------------------------- ---------------- ------------- ------------------------------------------------------------- -----------
  0                                                                   657 (99.4)       4 (0.6)       1                                                             ···
  1                                                                   620 (96.3)       24 (3.7)      8.907 (2.065‐38.409)                                          0.003
  ≥2                                                                  426 (77.5)       124 (22.5)    36.188 (8.534‐153.455)                                        \<0.001

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; CRS1, cardiorenal syndrome type 1; eGFR, estimated glomerular filtration rate; hs‐CRP, high‐sensitivity C‐reactive protein; NT‐proBNP, amino‐terminal pro--brain natriuretic peptide; OR, odds ratio.

Cutoff values for abnormal biomarker levels were eGFR≤71.29 mL/(min·1.73 m^2^), NT‐proBNP≥2573 pg/mL, and hs‐CRP≥8.03 mg/L.

Adjusted by age, sex, hemoglobin at admission, hematocrit at admission, albumin at admission, glucose at admission, previous coronary artery disease, previous hypertension, previous diabetes mellitus, previous chronic kidney disease, angiography, ACEI and/or ARB use after admission, and diuretic use after admission.

Discussion {#jah33530-sec-0020}
==========

To our knowledge, this is the first study to examine the predictive ability of a combination of 3 traditional biomarkers of heart failure: (NT‐proBNP), renal function (eGFR), and inflammation (hs‐CRP) for CSR1. The major findings of this study were these: (1) abnormal levels of NT‐proBNP, eGFR, and hs‐CRP at admission were independent risk factors for in‐hospital CRS1; (2) the sensitivity of NT‐proBNP, eGFR, and hs‐CRP were relatively high, but the specificity of hs‐CRP was relatively poor; (3) the discriminatory capability of the 3‐biomarker panel was stronger than those of the individual biomarkers; and (4) abnormal levels of 2 or more biomarkers based on the identified cutoff values were associated with an elevated risk of CRS1.

AMI is 1 of the critical conditions that can lead to CRS1. The majority of existing reports noted that CRS1 in patients with acute coronary syndrome was associated with longer hospital stay and higher in‐hospital mortality.[17](#jah33530-bib-0017){ref-type="ref"} Recently, in patients who were hospitalized for acute coronary syndrome, the risk of in‐hospital mortality associated with CRS1 was greater than the sum of the risks associated with acute heart failure and AKI.[10](#jah33530-bib-0010){ref-type="ref"} CRS1 also was responsible for more than half of all cases of in‐hospital mortality. In contrast to acute coronary syndrome, there are few reports in the literature on CRS1 in the setting of only AMI. Our study provides evidence that CRS1 may adversely affect clinical outcomes in AMI patients. In our cohort the all‐cause mortality and cardiovascular mortality in the CRS1 group were 9 times higher than those among the group of patients who did not develop CRS1. Therefore, it is important to understand the risk factors and develop methods for early prevention of the development of CRS1.

A large number of studies have evaluated the associations of various predictors with the occurrence of AKI in AMI patients and found that advanced age, hypertension, low body mass index, initial hemodynamic instability, extent of vessel disease, severe Killip class, abnormal heart rate, reduced GFR at presentation, longer door‐to‐needle time, increased spot urine albumin‐to‐creatinine ratio, hyperglycemia at admission, history of chronic kidney disease, and decreased hemoglobin levels are associated with worsening renal function (or AKI).[17](#jah33530-bib-0017){ref-type="ref"}, [18](#jah33530-bib-0018){ref-type="ref"}, [19](#jah33530-bib-0019){ref-type="ref"}, [20](#jah33530-bib-0020){ref-type="ref"}, [21](#jah33530-bib-0021){ref-type="ref"}, [22](#jah33530-bib-0022){ref-type="ref"} In the present study we found that baseline cardiorenal dysfunction and inflammation were independent predictors of CRS1 in patients with AMI, which is consistent with previous results. Furthermore, we found that NT‐proBNP, eGFR, and hs‐CRP had good discriminative ability for the prediction of CRS1. The reason may be based on the correlation of these markers with the pathophysiology mechanisms of CRS1.

Many studies have emerged in recent years trying to explain the pathophysiology of CRS1, and they have primarily focused on the hemodynamic and nonhemodynamic mechanisms. The traditional theory is that hypoperfusion of the kidneys followed by "forward failure" might lead to acute tubular necrosis, which is regarded as the key underlying mechanism contributing to renal dysfunction in the acute clinical setting.[23](#jah33530-bib-0023){ref-type="ref"}, [24](#jah33530-bib-0024){ref-type="ref"} However, a growing body of research indicates that elevations in right atrial pressure, which correlate with central venous pressure rather than a decline in cardiac output and/or cardiac index, are associated with declining renal function.[5](#jah33530-bib-0005){ref-type="ref"}, [25](#jah33530-bib-0025){ref-type="ref"}, [26](#jah33530-bib-0026){ref-type="ref"}, [27](#jah33530-bib-0027){ref-type="ref"}, [28](#jah33530-bib-0028){ref-type="ref"} NT‐proBNP has already been established as a diagnostic and prognostic marker in chronic as well as acute heart failure, and this protein is rapidly released from cardiomyocytes after stretching. Moreover, recent studies have reported that NT‐proBNP is a strong independent predictor of worsening renal function within 18 months in patients with systolic heart failure[29](#jah33530-bib-0029){ref-type="ref"} and a biochemical marker of integrated cardiorenal function in the chronic phase after myocardial infarction.[30](#jah33530-bib-0030){ref-type="ref"} In the present study we hypothesized that NT‐proBNP is an indirect indicator of elevations in central venous pressure and/or right atrial pressure during the pathophysiology of CRS1. Accordingly, we found that NT‐proBNP had good discriminatory ability and could serve as an indirect marker of CRS1 in patients with AMI.

In addition to hemodynamic pathways inflammation plays a pivotal role in the nonhemodynamic mechanisms of CRS1 pathophysiology. In a study by Virzi et al, serum levels of the proinflammatory cytokines tumor necrosis factor‐α and interleukin‐6 were significantly elevated in CRS1 patients compared with healthy controls.[31](#jah33530-bib-0031){ref-type="ref"} Another recent study found that elevated levels of inflammatory factors such as interleukin‐1β, endothelin‐1, interleukin‐10, and resolvin‐D1 were positively correlated with worsening renal function in patients with ACS.[7](#jah33530-bib-0007){ref-type="ref"} Among the various cytokines and mediators, hs‐CRP has received significant attention due to its association with atherosclerosis and cardiac disease as well as its prognostic value for heart failure and long‐term mortality.[32](#jah33530-bib-0032){ref-type="ref"}, [33](#jah33530-bib-0033){ref-type="ref"}, [34](#jah33530-bib-0034){ref-type="ref"} The results of the current study indicate that hs‐CRP is a powerful and independent predictor of CRS1. Despite its poor specificity, hs‐CRP showed relatively good sensitivity at a cutoff value of 8.03 mg/L. Our results are consistent with those of a previous report indicating that hs‐CRP \>9 mg/L at admission is an independent predictor of AKI in patients with ST‐elevation myocardial infarction following primary percutaneous coronary intervention.[35](#jah33530-bib-0035){ref-type="ref"} Interestingly, elevation of hs‐CRP not only is a marker of AKI but also plays a pathogenic role in AKI by inhibiting tubular epithelium cell regeneration and altering macrophage polarization.[36](#jah33530-bib-0036){ref-type="ref"}, [37](#jah33530-bib-0037){ref-type="ref"} Therefore, anti‐inflammatory treatment targeting the hs‐CRP pathway may offer a new therapeutic approach to preventing or treating CRS1.

So far, the ideal marker for early detection of CRS1 has remained elusive. Several novel biomarkers for early detection of AKI have been investigated in patients with heart failure, including cystatin C, neutrophil gelatinase‐associated lipocalin, N‐acetyl‐β‐D‐glucosaminidase, kidney injury molecule‐1, interleukin‐18, and tissue inhibitor of metalloproteinase‐2.[38](#jah33530-bib-0038){ref-type="ref"}, [39](#jah33530-bib-0039){ref-type="ref"} These indicators have different clinical significance and features. However, no single marker satisfied the conditions of high organ specificity, high sensitivity for diagnosis, and being reflective of the disease course. Therefore, a multimarker model has been proposed for risk prediction. The current analysis represents the first examination of the combination of NT‐proBNP, eGFR, and hs‐CRP for predicting CRS1 in patients with AMI. This combination of biomarkers may be used to predict CRS1 and to facilitate risk stratification of AMI patients.

Study Limitations {#jah33530-sec-0021}
-----------------

We acknowledge several limitations in our study. First, this was a single‐center study, and our findings may not apply to other samples of patients in whom CRS1 was defined according to different criteria. Second, we did not investigate the contribution of nephrotoxic drugs to CRS1 development. Although we performed adjustment for pharmacological treatments and the catheter laboratory procedure, the amount of contrast agent was unknown. Third, as discussed in other studies on CRS1, the measurement of serum creatinine for evaluation of dynamic changes in renal function was performed at variable time intervals in our study. Fourth, some baseline clinical variables may have been missed. Therefore, it is possible that unmeasured or residual confounding factors may explain some of our results. Last, it should be noted that our study was an observational study and not an interventional study. The characteristics and clinical course of CRS1 may have been influenced by different treatments, causing our results to differ slightly from those of later trials. Further prospective multicenter studies are needed to validate our findings and identify even better multimarker models including other existing biomarkers and parameters.

In summary, we assessed the performance of 3 traditional markers (NT‐proBNP, eGFR, and hs‐CRP) for detecting the development of CRS1 in a cohort of 2094 patients with AMI. These 3 simple markers are easy to measure and apply in clinical practice. Because of their relation to the pathophysiology of CRS1, NT‐proBNP, eGFR, and hs‐CRP at admission were found to be independent risk factors for in‐hospital CRS1 and to show good discriminative ability. The combination of the 3 biomarkers showed better predictive capability than any of the biomarkers individually. Abnormal levels of 2 or more of these markers according to the identified cutoff values were associated with an elevated risk of CRS1. Therefore, the multimarker panel of NT‐proBNP, eGFR, and hs‐CRP may assist in the prediction of CRS1 and the corresponding risk stratification of patients with AMI.
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